Endometrium-Karzinom

• Literatur

• 1 Robert Koch-Institut. Krebs in Deutschland für 2019/2020. Accessed December 17, 2024 at: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_2023.pdf?__blob=publicationFile
• 2 Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543-1551
• 3 Pennant ME, Mehta R, Moody P. et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG 2017; 124: 404-411
• 4 Arnold M, Karim-Kos HE, Coebergh JW. et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2015; 51: 1164-1187
• 5 Hiller GGR, Höhn AK, Mayr D. et al. Molecular classification of endometrial carcinoma-a short summary for clinical use. Pathologie 2023; 44: 392-400
• 6 Berek JS, Matias-Guiu X, Creutzberg C. et al. FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet 2023; 162: 383-394
• 7 Gaffney D, Matias-Guiu X, Mutch D. et al. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution. Gynecol Oncol 2024; 184: 245-253
• 8 Crosbie EJ, Kitson SJ, McAlpine JN. et al. Endometrial cancer. Lancet 2022; 399: 1412-1428
• 9 Concin N, Matias-Guiu X, Vergote I. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31: 12-39
• 10 Creutzberg CL, Nout RA, Lybeert MLM. et al. Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: e631-e638
• 11 Keys HM, Roberts JA, Brunetto VL. et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-751
• 12 Randall ME, Filiaci V, McMeekin DS. et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol 2019; 37: 1810-1818
• 13 Boer SM, Powell ME, Mileshkin L. et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 295-309
• 14 Matei D, Filiaci V, Randall ME. et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 2019; 380: 2317-2326
• 15 León-Castillo A, de Boer SM, Powell ME. et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit FromAdjuvant Therapy. J Clin Oncol 2020; 38: 3388-3397
• 16 Albright BB, Monuszko KA, Kaplan SJ. et al. Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2021; 225: 237 e231-237 e224
• 17 Oaknin A, Gilbert L, Tinker AV. et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer 2022; 10: e003777
• 18 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1-10
• 19 Makker V, Colombo N, Casado Herráez A. et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022; 386: 437-448
• 20 Westin SN, Moore K, Chon HS. et al. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol 2024; 42: 283-299